Israel
Mileutis Ltd. is a biotechnology startup founded in 2004 with a focus on developing safe and residual-free therapies for animal and human health. Their flagship products, Imilac™ and Milac™, are targeted at addressing mastitis, a major concern in the dairy industry. These products, derived from milk peptides and specific protein fragments, offer a non-residual, non-antibiotic solution for dairy farms.
By reducing the need for antibiotics in animal health management, Mileutis' innovative therapies not only improve the well-being of dairy cows but also provide significant economic value to farmers by boosting milk yield and productivity. The company's approach aligns with the growing global concern about the use of antibiotics in agriculture and the potential impact on human health.
The recent $20.00M Venture Round investment in Mileutis by Novaquest Capital Management on 19 October 2020 underscores investor confidence in the startup's potential to disrupt the dairy industry and address critical health and economic challenges. With headquarters in Israel, Mileutis is poised to make a substantial impact in the biotechnology and animal health sectors.
